Platelet-rich fibrin treatment of medication-related osteonecrosis of the jaw followed up for two years

The use of platelet-rich fibrin (PRF) in surgery represents a new alternative method of treatment of Medication-related osteonecrosis of the jaws. This report presents a case of a patient undergoing PRF treatment. The patient is a 76-year-old male who was admitted for treatment in 2018 at the Clinic for Maxillofacial Surgery with osteonecrosis of the lower jaw on the right side. In 2012, he was diagnosed with prostate cancer and underwent bilateral orchiectomy followed by a therapy with Denosumab (trade names Prolia and Xgeva), a monoclonal antibody that works as receptor activator of nuclear factor kappa-Β ligand (RANKL) inhibitor. The patient was diagnosed with medication-related osteonecrosis of the mandible jaw in 2017 after tooth extraction. The treatment was performed at the Clinic of Maxillofacial Surgery of St. George University Hospital, Plovdiv, Bulgaria. When initial antibiotic therapy failed, surgical therapy was undertaken using PRF. The patient was followed-up for two years and no osteonecrotic lesion was detected recurring in the intervention area. Biomed Rev 2020; 31: 161-163